Literature DB >> 24815564

Opportunistic infections in patients with pemphigus.

Yael A Leshem1, Michael Gdalevich2, Michael Ziv3, Michael David4, Emmilia Hodak4, Daniel Mimouni4.   

Abstract

BACKGROUND: Opportunistic infections (OIs) can be defined as infections in immunosuppressed patients that are more frequent or severe because of immunosuppression. The literature on OIs in pemphigus is sparse.
OBJECTIVE: We assessed the incidence, risk factors, and characteristics of OIs in patients with pemphigus.
METHODS: This was a historical prospective study following a cohort of 172 patients with newly diagnosed pemphigus for the development of OIs.
RESULTS: Fourteen patients developed OIs at a mean of 4 months from the time of diagnosis while taking a mean dose of 0.8 mg/kg/day of prednisone, 5 in conjunction with azathioprine. The risk of developing an OI in the first year after the diagnosis of pemphigus was 9.3%, subsequently dropping to 0. Advanced age and possibly diabetes were found to be risk factors for OI development. Infectious agents included Nocardia, cytomegalovirus, Legionella, and Listeria. Two patients died within 2 months of OI diagnosis, and 2 more had neurologic impairment. LIMITATIONS: Limitations include the extraction of historical data and the cohort originating from a single geographic region.
CONCLUSION: OIs present in a significant number of patients with pemphigus during the first year after the diagnosis of pemphigus, with potential deleterious effects. Older and possibly diabetic patients are at increased risk. Physician vigilance and patient education on limiting pathogen exposure is recommended.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  corticosteroids; cytomegalovirus; legionella; listeria; nocardia; opportunistic infection; pemphigus

Mesh:

Substances:

Year:  2014        PMID: 24815564     DOI: 10.1016/j.jaad.2014.03.020

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

Review 1.  Setting the target for pemphigus vulgaris therapy.

Authors:  Christoph T Ellebrecht; Aimee S Payne
Journal:  JCI Insight       Date:  2017-03-09

Review 2.  Update on fogo selvagem, an endemic form of pemphigus foliaceus.

Authors:  Valeria Aoki; Evandro A Rivitti; Luis A Diaz
Journal:  J Dermatol       Date:  2015-01       Impact factor: 4.005

3.  Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis.

Authors:  Alex M Rokni; Marissa Ayasse; Adnan Ahmed; Lauren Guggina; Robert W Kantor; Jonathan I Silverberg
Journal:  Arch Dermatol Res       Date:  2022-03-09       Impact factor: 3.017

4.  Is there an association between pemphigus and hepatitis viruses? A population-based large-scale study.

Authors:  Khalaf Kridin; Shira Zelber-Sagi; Doron Comaneshter; Arnon D Cohen
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

5.  Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis.

Authors:  Kyle T Amber; Aniek Lamberts; Farzan Solimani; Arianna F Agnoletti; Dario Didona; Ilona Euverman; Emanuele Cozzani; Lee Haur Yueh; Giovanni Di Zenzo; Yael Anne Leshem; Daniel Mimouni; Michael Hertl; Barbara Horvath
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

Review 6.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

7.  Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study.

Authors:  Adrian Baican; Roxana Chiorean; Daniel Corneliu Leucuta; Corina Baican; Sorina Danescu; Dorina Ciuce; Cassian Sitaru
Journal:  Orphanet J Rare Dis       Date:  2015-04-22       Impact factor: 4.123

8.  Gastrointestinal cytomegalovirus disease in a patient with pemphigus vulgaris treated with corticosteroid and mycophenolate mofetil.

Authors:  Luiza Barbosa Oliveira; Celina Wakisaka Maruta; Denise Miyamoto; Fernanda Aburesi Salvadori; Claudia Giuli Santi; Valeria Aoki; Amaro Nunes Duarte-Neto
Journal:  Autops Case Rep       Date:  2017-03-30

9.  Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Authors:  Jia Chen; Xuming Mao; Wenling Zhao; Bingjie Zhang; Xinyi Chen; Chenyang Yu; Zehui Zheng; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

10.  Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity.

Authors:  Naiyu Lin; Qingxiu Liu; Menglei Wang; Qian Wang; Kang Zeng
Journal:  PeerJ       Date:  2018-08-03       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.